Cargando…

Prevention of Invasive Aspergillus Fungal Infections with the Suspension and Delayed-Release Tablet Formulations of Posaconazole in Patients with Haematologic Malignancies

Posaconazole is a triazole antifungal used to prevent invasive fungal infections (IFIs) in patients receiving chemotherapy or haemotopoietic stem cell transplantation. Due to highly variable bioavailability of the oral suspension formulation, a delayed-release tablet was developed which showed impro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leclerc, Elisabeth, Combarel, David, Uzunov, Madalina, Leblond, Véronique, Funck-Brentano, Christian, Zahr, Noël
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785994/ https://www.ncbi.nlm.nih.gov/pubmed/29374234 http://dx.doi.org/10.1038/s41598-018-20136-3

Ejemplares similares

Clinical Outcomes of the Oral Suspension vs Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections
por: Tallman, Gregory B, et al.
Publicado: (2017)

Clinical Outcomes of Oral Suspension versus Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections
por: Furuno, Jon P., et al.
Publicado: (2018)

Evaluation of Serum Posaconazole Concentrations in Patients with Hematological Malignancies Receiving Posaconazole Suspension Compared to the Delayed-Release Tablet Formulation
por: Belling, Morgan, et al.
Publicado: (2017)

1469 Posaconazole salvage treatment for invasive fungal infection : a single center experience with utilization of posaconazole oral suspension or delayed-released tablet
por: Kim, Jong Hun, et al.
Publicado: (2014)

Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infections
por: Wiederhold, Nathan P
Publicado: (2015)

Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease
por: Cornely, Oliver A., et al.
Publicado: (2016)

Comparison of Plasma Concentrations of Posaconazole with the Oral Suspension and Tablet in Korean Patients with Hematologic Malignancies
por: Suh, Hyeon Jeong, et al.
Publicado: (2017)

In vitro susceptibility to amphotericin B, itraconazole, voriconazole, posaconazole and caspofungin of Aspergillus spp. isolated from patients with haematological malignancies in Tunisia
por: Gheith, Soukeina, et al.
Publicado: (2014)

941. Isavuconazole Prophylaxis Against Invasive Fungal Infection: A Pooled Analysis with a Comparison of Posaconazole Delayed-release Tablet Prophylaxis
por: Lee, Chaeryoung, et al.
Publicado: (2021)

1558. A Population Pharmacokinetic Model for Posaconazole Intravenous Solution and Oral Powder for Suspension Formulations in Pediatric Patients With Neutropenia
por: Winchell, Gregory A, et al.
Publicado: (2019)

2546. Administration of Crushed Posaconazole Delayed Release Tablets Failed to Achieve Therapeutic Levels
por: Kane, Nicholas, et al.
Publicado: (2023)

Posaconazole in the management of refractory invasive fungal infections
por: Langner, Stefan, et al.
Publicado: (2008)

Cost-Effectiveness of Posaconazole Tablets for Invasive Fungal Infections Prevention in Acute Myelogenous Leukemia or Myelodysplastic Syndrome Patients in Spain
por: Cámara, Rafael, et al.
Publicado: (2017)

Prevention of invasive fungal infections in immunocompromised patients: the role of delayed-release posaconazole
por: Soysal, Ahmet
Publicado: (2015)

Role of New Antifungal Agents in the Treatment of Invasive Fungal Infections in Transplant Recipients: Isavuconazole and New Posaconazole Formulations
por: Li, Julius, et al.
Publicado: (2015)

Pharmacokinetic/pharmacodynamic study of posaconazole delayed-release tablet in a patient with coexisting invasive aspergillosis and mucormycosis
por: Leelawattanachai, Pannee, et al.
Publicado: (2019)

Clinical pharmacokinetics and dose recommendations for posaconazole gastroresistant tablets in children with cystic fibrosis
por: Bentley, Siân, et al.
Publicado: (2021)

Sample Preparation of Posaconazole Oral Suspensions for Identification of the Crystal Form of the Active Pharmaceutical Ingredient
por: Lykouras, Michail, et al.
Publicado: (2020)

Evaluation of Posaconazole Pharmacokinetics in Adult Patients with Invasive Fungal Infection
por: Allegra, Sarah, et al.
Publicado: (2017)

The Effect of Posaconazole, Itraconazole and Voriconazole in the Culture Medium on Aspergillus fumigatus Triazole Resistance
por: Mroczyńska, Martyna, et al.
Publicado: (2020)

The use of posaconazole delayed-release tablets in the successful treatment of suspected mucormycosis in a bottlenose dolphin (Tursiops truncatus) calf
por: Marques, Gonçalo N., et al.
Publicado: (2021)

The successful use of amphotericin B followed by oral posaconazole in a rare case of invasive fungal sinusitis caused by co-infection with mucormycosis and aspergillus
por: Mahomed, Sharana, et al.
Publicado: (2015)

Effectiveness of Posaconazole in Recalcitrant Fungal Keratitis Resistant to Conventional Antifungal Drugs
por: Altun, A., et al.
Publicado: (2014)

Evaluation of Hydroxychloroquine Blood Concentrations and Effects in Childhood-Onset Systemic Lupus Erythematosus
por: Zahr, Noël, et al.
Publicado: (2021)

A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers
por: Krishna, G., et al.
Publicado: (2012)

413. Intravenous and Tablet Formulation of Posaconazole in Antifungal Therapy and Prophylaxis: A Retrospective, Non-Interventional, Multicenter Analysis of Patients Treated in German Tertiary-Care Hospitals
por: Heimann, Sebastian M, et al.
Publicado: (2018)

Posaconazole for lobomycosis
por: Pasqualotto, Alessandro C., et al.
Publicado: (2021)

Safety, Tolerability, and Pharmacokinetics (PK) of Posaconazole (POS) Intravenous (IV) Solution and Oral Powder for Suspension in Children With Neutropenia
por: Groll, Andreas H, et al.
Publicado: (2017)

A non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia
por: Arrieta, Antonio C., et al.
Publicado: (2019)

Posaconazole oral suspension for secondary antifungal prophylaxis in allogeneic stem cell transplantation recipients: a retrospective study
por: Ye, Peipei, et al.
Publicado: (2022)

Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections
por: Zoller, Emily, et al.
Publicado: (2010)

Physiologically Based Pharmacokinetic Model Development and Verification for Bioequivalence Testing of Bempedoic Acid Oral Suspension and Reference Tablet Formulation
por: Amore, Benny M., et al.
Publicado: (2023)

Pharmacokinetics and Pharmacodynamics of Posaconazole
por: Chen, Lu, et al.
Publicado: (2020)

Itraconazole, Voriconazole, and Posaconazole CLSI MIC Distributions for Wild-Type and Azole-Resistant Aspergillus fumigatus Isolates
por: Buil, Jochem B., et al.
Publicado: (2018)

1161. Effectiveness of Posaconazole in the Treatment of Rare Invasive Fungal Infections: A Systematic Literature Review
por: Bernauer, Mark, et al.
Publicado: (2020)

755. Posaconazole versus voriconazole as antifungal prophylaxis for invasive fungal diseases in patients with hematological malignancies
por: Almutairy, Reem F, et al.
Publicado: (2020)

Population Pharmacokinetics of Posaconazole in Immune-Compromised Children and Assessment of Target Attainment in Invasive Fungal Disease
por: McCann, Sean, et al.
Publicado: (2023)

Total and Unbound Pharmacokinetics of Cefiderocol in Critically Ill Patients
por: Zahr, Noël, et al.
Publicado: (2022)

Posaconazole and isavuconazole induced hypomagnesaemia
por: Burston, John, et al.
Publicado: (2018)

El drama de los venenos : estudio sobre la sociedad del siglo XVII
por: Funck-Brentano, Frantz, 1862-1947

Cannot write session to /tmp/vufind_sessions/sess_1dk5artmuvieheesc2nolhctp2